About this Study
ABOUT OUR STUDY DRUG
Epeleuton’s active ingredient is a fatty acid, 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester. 15(S)-HEPE is found naturally in the body. In previous preclinical studies it has been shown to have a positive effect on the health of red blood cells and hemolytic anemia (when red blood cells are destroyed faster than they can be made), on blood vessel inflammation and on organ damage.
WHAT IS THE AIM OF THE STUDY?
- To assess how Epeleuton targets various aspects of Sickle Cell Disease (SCD)
- To understand how Epeleuton capsules are processed in the body and
- To continue to review how well Epeleuton is tolerated
You may be compensated for your time and travel while participating.
Insurance is not needed as the pharmaceutical company fund the research studies.
You will have access to our medical research staff during the study.
You may withdraw consent or decide to stop participating at any time during the study.
Your information is kept confidential, protected and is never shared without your permission.
WHY EMBARK ON THIS UNIQUE OPPORTUNITY?
- Natural active ingredient
- Convenient Oral Medication (taken with food or within 30 minutes of a meal)
- Good safety profile
WHAT DO PARTICIPANTS RECEIVE?
- Coverage of expenses linked to study visits, including transportation and meals
- Access to our complimentary car service for added convenience
WHAT’S REQUIRED TO DO?
- Take Epeleuton capsules twice daily for 4 months
- Attend just 6 clinic visits
- Undergo blood draws at each visit
- Maintain a daily electronic Diary on your personal device
